Engflag

Lumios

Quick links to important sections

Lumios

Lumios_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lumios

Quick Facts

Property Description
Active ingredient Tranilast
Form Oral Capsule
Pharmacological Class Antiallergic Agent, Mast Cell Stabilizer
Origin Synthetic Derivative (Anthranilic Acid)

What Type of Medicine is Lumios? (Identity and Classification)

Lumios is a synthetic small molecule drug that is pharmacologically classified as an antiallergic agent and a specialized mast cell stabilizer. Its sole active component is the substance Tranilast, which is chemically defined as an anthranilic acid derivative. This classification confirms the drug's specialized design to regulate immune responses. Unlike many general antiallergy compounds, Tranilast is clinically recognized for its targeted ability to interfere with multiple pathways.

Composition and Form of the Lumios Preparation

The medicinal preparation of Lumios is an oral capsule, intended for systemic absorption and action throughout the body. As a single-ingredient product, its therapeutic effect relies exclusively on the Tranilast active component, which is formulated with standard pharmaceutical excipients necessary for encapsulation. This form is often prescribed to adult patients, offering the advantage of convenient oral intake compared to topical solutions. The systemic delivery system is a key factor, providing comprehensive, internal management where localized treatments would be insufficient.

The General Purpose and Unique Action of Tranilast

The general purpose of Lumios is to provide systemic support that manages both allergic hypersensitivity and inappropriate tissue response. It functions primarily as a mast cell stabilizer, preventing immune cells from releasing inflammatory mediators like histamine that drive allergic reactions. Uniquely, Tranilast also exhibits an established anti-fibrotic agent profile, meaning it helps to regulate excessive tissue repair and scarring. This distinct, dual mechanism is a key differentiator, making it suitable for situations requiring both allergy control and the modulation of fibrotic processes.

What side effects are possible with Lumios?

Possible Side Effects and Safety Information

The safety profile for Lumios (Tranilast oral capsule) is defined by regulatory documents that classify adverse reactions by their occurrence rate and the body system affected. All safety information provided herein is strictly based on official government regulatory sources.

Adverse Reaction Classification and Scope

Adverse reactions are formally categorized into two main tiers based on official prescribing information: Most Commonly Reported events, and Rarely Seen Initial Symptoms of Serious Reactions.

Classification Examples of Reactions (by SOC)
Most Commonly Reported Skin (e.g., rash, exfoliation, itching); Gastrointestinal (e.g., loss of appetite); Nervous System (headache); Reproductive System (abnormal menstruation).
Rarely Seen Initial Symptoms Symptoms related to potential Hepatobiliary (jaundice), Renal (decreased urine output), or Hematological Disorders (e.g., fever, bleeding tendency).

Serious Systemic Adverse Reactions

Regulatory documentation specifically identifies the potential for certain serious systemic effects that, while rare, require particular vigilance. These include Hepatic Dysfunction, Renal Dysfunction, and significant Hematological Disorders (such as leukopenia or thrombocytopenia). These systemic effects are organized by System-Organ Class (SOC) in regulatory safety summaries.

Population-Specific Safety Constraints

The official labeling includes specific safety considerations for certain patient groups. Caution is advised for individuals with pre-existing liver disorder or kidney disorder. Furthermore, the drug is subject to regulatory constraint or contraindication in women who are pregnant, possibly pregnant, or breastfeeding, based on official safety assessments.

Safety-Related Restrictions

Official documents note a safety risk related to co-administration with certain other medicines. The use of Lumios with the anticoagulant Warfarin may pose a risk due to the potential for an interaction that could increase the risk of bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official documentation regarding overdose and required emergency response for products associated with Lumios is based on the specific active component, outlining distinct toxicological profiles and mandated actions.

For the component Mosunetuzumab-axgb, the regulatory focus is on the immediate management of severe systemic toxicities rather than a simple acute overdose. Life-threatening events include Cytokine Release Syndrome (CRS), characterized by fever, hypotension, and hypoxia, and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which involves confusion, disorientation, and seizures. The documentation mandates that at the first sign of CRS or ICANS, patients must be immediately evaluated for hospitalization and provided specific supportive care.

For the component Brimonidine Tartrate ophthalmic solution, the overdose profile highlights a serious risk associated with accidental oral ingestion. Systemic overdose, particularly in infants and children under 2 years of age, is documented to cause severe symptoms including apnea, bradycardia, hypotension, and respiratory depression. Regulatory guidance states that immediate medical attention must be sought following any accidental ingestion in this population. Treatment is described as symptomatic and supportive, and no specific antidote is known. The official labeling underscores that severe systemic effects in young children require urgent intervention.

Therapeutic Uses of Lumios

Quick Facts: Primary Therapeutic Domains

  • Relapsed or Refractory Follicular Lymphoma: May be utilized in certain adult patients who have progressed after receiving two or more prior systemic therapies.
  • Intraoperative Breast Cancer Imaging: Used as an adjunct agent to assist surgeons in the visual detection of cancerous tissue during lumpectomy procedures.
  • Ocular Redness: Employed as an over-the-counter option for the temporary relief of eye redness caused by minor irritations.

What Lumios Treats: Main Uses and Benefits

Lumios is a term associated with different medications or applications, each serving a distinct therapeutic purpose. One approved application involves its use as an imaging agent in adult patients with breast cancer. In this context, the compound assists in the intraoperative detection of cancerous tissue within the lumpectomy resection cavity, supplementing the primary surgical specimen removal.

Another application, under the brand name Lunsumio, addresses specific hematologic malignancies. This form is indicated for the management of relapsed or refractory follicular lymphoma in adult patients who have already undergone two or more lines of systemic treatment. Its administration is intended to engage the immune system to target certain malignant B cells, which can contribute to the management of this specific blood cancer. Finally, a different formulation, Lumify, provides temporary relief from ocular redness due to minor eye irritations.

The use of any medication or medical product should be discussed with a qualified healthcare provider.

Eligibility and Restrictions for Use

The name Lumios is associated with three distinct products, and official eligibility is defined separately for each by regulatory authorities.

General Eligibility and Contraindications

Product Type Allowed Population Key Restrictions / Contraindications
Oral Capsule (Tranilast) Primarily Adults (in authorized regions) Contraindicated in women who are or might become pregnant. Caution is required in patients with pre-existing liver or kidney disorders [Source 3.4].
Injection (Mosunetuzumab-axgb) Adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy [Source 1.2]. No absolute contraindications are listed in the Prescribing Information. Females must use effective contraception and not breastfeed during treatment [Source 2.1].
Ophthalmic Solution (Brimonidine) Adults and children ge 5 years of age (for the redness relief formulation) [Source 3.1]. Contraindicated in neonates and infants (under 2 years old) and patients with known hypersensitivity to any ingredient [Source 3.2].

Age and Physiological Status

For the injection and oral capsule, use in the pediatric population is not established. The ophthalmic solution is strictly prohibited for children under two years of age due to risk of serious adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for the medicines associated with Lumios is structured around managing specific drug-drug interactions, which include mandated prohibitions, timing rules, and metabolic cautions.

Official Interaction Statements

Interaction Type Interacting Substances/Classes Constraint / Required Action (Official Documentation)
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Strictly prohibited co-administration with Brimonidine ophthalmic.
Pharmacodynamic Effects CNS Depressants, Antihypertensives, Cardiac Glycosides Use with caution due to documented additive systemic effects, such as increased drowsiness or hypotension.
Metabolic Interference CYP2C9 Inhibitors (e.g., Fluconazole) May increase Tranilast plasma levels. Co-administration requires caution.
Metabolic Interference CYP2C9 Inducers (e.g., Rifampin) May decrease Tranilast plasma levels. Co-administration requires caution.
Timing Requirements Corticosteroids, Antihistamines, Antipyretics Mandatory administration at specified intervals prior to Mosunetuzumab-axgb infusion.

Tranilast is also documented as an inhibitor of the UGT1A1 enzyme, which may lead to increased exposure of other medicines that are substrates for this enzyme. Regulatory information notes that interactions may be more significant in patients with hepatic or renal disorders, due to altered clearance. The ophthalmic form requires caution regarding alcohol, which is listed as a potential CNS depressant contributing to additive effects.

Mechanism of Action

The activity of Lumios (Tranilast) is governed by a multi-target pharmacodynamic profile that modulates two distinct, yet interconnected, biological processes: acute inflammatory signaling and chronic tissue remodeling.

️ Inhibiting Acute Mediator Release

This mechanism involves a targeted action on the mast cell exocytosis machinery, which prevents the sudden and massive release of pre-formed inflammatory mediators, particularly histamine. By inhibiting the exocytosis of these immune cells, the drug leads to reduced systemic signaling of acute mediators and restricts mediator release following specific molecular triggers.

‍ Suppressing Foundational Inflammation (NLRP3 Pathway)

Tranilast acts as a specific inhibitor of the NLRP3 inflammasome, a crucial sensor complex that drives chronic inflammation. By binding directly to the NACHT domain of the NLRP3 protein , the drug blocks the assembly of this complex, thereby preventing the processing of pro-IL-1β into its active form. This action suppresses a source of pro-inflammatory signaling.

Modulating Tissue Structure and Proliferation

The drug also engages a distinct anti-fibrotic mechanism by modulating the TGF-β/SMAD2 signaling pathway. This activity inhibits fibroblast proliferation and suppresses the synthesis and deposition of collagen and fibronectin. This results in modulated connective tissue synthesis by constraining the deposition of Extracellular Matrix components.

Dosage and Administration Information

The usage protocols for the preparations associated with the name Lumios are highly dependent on the specific active ingredient and administration route. Administration is classified into three distinct use contexts: Intravenous (IV) infusion, Topical Ophthalmic application, and Oral capsule intake.

Administration Overview by Route

Administration Element Intravenous (Follicular Lymphoma) Topical Ophthalmic (Ocular Redness)
Route of Administration Intravenous (IV) Infusion Topical Ophthalmic (Drops)
Dosing Schedule Step-up dosing required in Cycle 1 (e.g., 1 mg, 2 mg, 60 mg), followed by maintenance doses. One drop per dose in the affected eye(s).
Frequency Administered in 21-day cycles, starting weekly, then every 21 days thereafter. Three times daily (TID), with doses spaced approximately eight hours apart.

Procedural and Labeled Constraints

The IV infusion protocol (for Mosunetuzumab-axgb) is a fixed-duration regimen, which typically concludes after 8 or 17 cycles. This administration requires mandatory premedication before initial doses and careful dilution prior to infusion. Infusion rates are specified, starting at a minimum of 4 hours and potentially reducing in later cycles.

For the Topical Ophthalmic solution (Brimonidine tartrate), the administration is subject to timing constraints: if other topical eye products are used, a minimum of five minutes must separate each instillation. Furthermore, this product is contraindicated in pediatric patients younger than 2 years of age.

The oral capsule (Tranilast identity) is intended for daily or divided daily use and must be swallowed whole.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lumios (Tranilast)

Evidence for Managing Keloids and Hypertrophic Scars

Research has examined Lumios (Tranilast) in the context of abnormal tissue growth, specifically in conditions known as keloids and hypertrophic scars. Studies, including Randomized Controlled Trials (RCTs), monitored the agent's measured patterns on objective scar assessments (like the VSS) and patient-reported outcomes like pain and itching intensity. The populations was evaluated in include both adults and children.

The findings describe patterns observed in the studies where measurements in scar quality scales and patient-reported measures of pain and itching was recorded during the study periods. Research has also explored outcomes related to tissue thickening. Long-term effects are not fully established, and comparative evidence is lacking against established alternative management strategies for scar treatment.

Evidence for Allergic Airway Conditions (Bronchial Asthma)

Lumios was studied for its use in managing chronic allergic airway inflammation. The evidence base includes older Randomized Controlled Trials (RCTs) that monitored measurements of pulmonary function tests (such as FEV1) and the recording of attack frequency in people with persistent asthma. Researchers monitored outcomes related to systemic or functional imbalance.

The findings describe patterns observed in the studies regarding measurements in FEV1 and symptom scores over short-term study periods. Comparative evidence is lacking against other established systemic treatments used for asthma management, and comprehensive data on sustained, long-term maintenance is not well-established.

Understanding Research Gaps and Uncertainty

Despite the existing body of clinical research, there are areas where certainty remains low. The evidence quality varies across studies, and comparative evidence is lacking for many modern, standard treatments across all indications. Evidence is also limited for certain groups, meaning data for certain groups remain insufficient, particularly for individuals with specific comorbidities or in pregnant populations.

Key Studies & References

  1. Tranilast: a review of its therapeutic applications
  2. Tranilast (INN, brand name Rizaben) is an antiallergic drug (Regulatory and Historical Context)

How should Lumios be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Lumios (Tranilast oral capsule) must strictly adhere to regulatory mandates to maintain its stability. The medicine must be kept away from light, heat, and moisture. This environmental protection is essential for the capsule's integrity.

For safety, it is an official requirement that the product be stored out of the sight and reach of children at all times.

Regarding disposal, any remaining or unused portion of the medicine must be discarded. Disposal must not be carried out via household waste or wastewater, and must instead be managed according to local pharmaceutical waste regulations to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagJapan

Equivalent of Lumios found in:

A-Z Index: